FIGURE

Fig. 7

ID

ZDB-FIG-250327-7

Publication

Hua et al., 2025 - Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance

Other Figures

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

All Figure Page

Back to All Figure Page

Fig. 7

Representative images of cell proliferation in a zPDX model derived from patients who are clinically resistant to osimertinib (scale bar, 500 µm). The number of xenografts analyzed is indicated in the corresponding images. NC, negative control; Osi, osimertinib; Anl, anlotinib; Osi + Anl, osimertinib combined with anlotinib; zPDX, zebrafish patient-derived xenograft.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Transl Lung Cancer Res